Colostrinin®: A Proline-Rich Polypeptide (PRP) Complex Isolated from Ovine Colostrum for Treatment of Alzheimer's Disease. A Double-Blind, Placebo-Controlled Study

Archivum Immunologiae et Therapiae Experimentalis

Volumn 47, Issue 6, 1999, Pages 377-385

  Leszek, Jerzy ^a   Inglot, Anna D ^b   Janusz, Maria ^b   Lisowski, Józef ^b   Krukowska, Katarzyna ^b   Georgiades, Jerzy A ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c ReGen Therapeutics Plc   (United Kingdom)

Author keywords

A proline rich polypeptide (PRP) complex Colostrinin ; Alzheimer's disease; Therapy

Indexed keywords

IMMUNOLOGICAL ADJUVANT; PEPTIDE; PROLINE RICH PROTEIN; PROLINE-RICH POLYPEPTIDE; SELENIUM; COLOSTRININ; POLYPEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BIOAVAILABILITY; CHEMISTRY; CHICKEN; CLINICAL TRIAL; COLOSTRUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MOUSE; PREGNANCY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RAT; SAFETY; SHEEP; ADULT; AGED; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG ISOLATION; DRUG SAFETY; MALE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AVAILABILITY; CHICKENS; COLOSTRUM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MICE; PEPTIDES; PREGNANCY; RATS; SAFETY; SELENIUM; SHEEP;

EID: 0033253232     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. BARGER S. W., HORSTER D., FURUKAWA K., GOODMAN Y., KRIEGLSTEIN J. and MATSON M. P. (1995): Tumor necrosis factors α and β protect neurons against amyloid β peptide toxicity. Proc. Natl. Acad. Sci. USA, 92, 9328-9332.
2. COEN R. F., SWANWICK G. A., O'BOYLE C. A. and COACKLEY D. (1997): Behavior disturbance and other prediction of carer burden in Alzheimer's disease. Int. J. Geriat. Psychiatry, 12, 331-336.
3. DARDENNE M. and SAVINO W. (1996): Interdependence of the endocrine and immune system. Adv. Neuroimmunol., 6, 297-307.
4. ESTUS S., GOLDE T. E., KUNISHITA T., BLADES J., LOWERY D., EISEN M., USIAK M., QU X., TABIRU T., GREENBERG B. D. and YOOUNKIN S. A. (1992): Potentially an amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science, 255, 726-728.
5. EZZEL C. (1992): Alzheimer's alchemy. Turning an innocuous-cell protein into brain-wrecking beta amyloid. Science News, 114, 152-153.
6. FRIEDMAN E. M. and IRWIN M. R. (1997): Modulation of immune cell function by the autoimmune nervous system. Pharmacol. Ther., 74, 27-38.
7. FOLSTEIN M. F., FOLSTEIN S. E. and MCHUGH P. R. (1975): Mini-mental-state: a practical method for grading the cognitive state of patients for clinician. J. Psychiatr. Res., 12, 189-198.
8. GEODERT M. (1993): Protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci., 16, 460-465.
9. GEORGIADES J. A., and FLEISCHMANN W. R. JR. (1996): Oral application of cytokines. Biotherapy, 8, 205-212.
10. ™. Eur. Cytokine Netw., 7, 511.
11. GIBBS W. (1998): Dogma overturned. Sci. Am., 11, 19-20.
12. GOLDO T. E., ESTUS S., YOUNKIN L. H., SELKOE D. J. and YOUNKIN S. G. (1992): Processing of the amyloid protein precursor to potentially amylodogenic derivatives. Science, 255, 728-730.
13. INGLOT A. D., GELDER F. and GEORGIADES J. A. (1998): Tumor-associated antigens are cytokine inducers and hyporeactivity factors in the immune system. Biotherapy, 11, 27-37.
14. ™: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch. Immunol. Ther. Exp., 44, 215-223.
15. ™ identified as a new cytokine. Eur. Cytokine Netw., 7, 512.
16. JANUSZ M. and LISOWSKI J. (1993): Proline-rich polypeptide (PRP) an immunomodulatory peptide from ovine colostrum. Arch. Immunol. Ther. Exp., 41, 275-279.
17. JANUSZ M., STAROŚCIK K., ZIMECKI M., WIECZOREK Z. and LISOWSKI J. (1981): Chemical and physical characterization of a proline-rich polypeptide from sheep colostrum. Biochem. J., 199, 9-15.
18. KLOSZEWSKA I. and KWIECIŃSKA E. (1998): Relations between the psychical condition and behavior disorders in dementia patient and the feeling of a "burden" in care giver. Psychogeriatric Ann., 1, 59-66.
19. KNAPP M. J., KNOPMAN D. S., SOLOMON P. R., PENTELBURY W. W., DAVIS C. S. and GRACON S. T. (1994): A 50-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. Tacrine study group. JAMA, 271, 985-991.
20. KNUSSEL R., BECK K. D., WINSLOW J. W., ROSENTHAL A., BURTON L. E., WIDMER H. R., NICOLICS K. and HEFTI F. (1992): Brain-derived neutrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult brain. J. Neurol. Sci., 12, 4391-4402.
21. Li J. J., HUANG W., HOWORTH P., SONI R., FULLER M., SANER H., NOVOTNIK A. C. and SUZDAK P. D. (1997): Neurotropic immunophilium ligands stimulate structural and fuctional recovery in neurogenerative models. Proc. Natl. Acad. Sci. USA, 94, 2019-2024.
22. MAZUR-KALECKA B., FRACKOWIAK J., LE VINE III H., HASKET T. and WIŚNIEWSKI H. M. (1997): Factors produced by activated macrophages reduce accumulation of Alzheimer's β amyloid protein in vascular smooth muscle cells. Brain Res., 760, 255-260.
23. MCKHAN G., DRACHMAN D., FOUSTEIN M., KATZMAN R., PRICE D. and STADLAN E. M. (1984): Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspicies of Department of Health and Human Services task force on Alzheimer's disease. Neurology, 34, 939-944.
24. MEDA L., CASSATELLA M. A., SZENDREL G., OTVAS L. JR., BARAN P., VILLALBA M., FERRARI D. and ROSSI F. (1995): Activation of the microglial cells by β amyloid protein and interferon γ. Nature, 374, 647-650.
25. NITSH R. M., BLUSZTAJN J. K., PITTAS A. G., SLACK B. E., GROUDON J. H. and WURTMAN R. J. (1992): Evidence for a membrane defect in Alzheimer's disease brain. Proc. Natl. Acad. Sci. USA, 89, 1671-1675.
26. ™, a polypeptide isolated from the early milk facilities the learning and memory in rats. Pharmacol. Biochem. Behav., 64, 183-189.
27. RINGHEIM G. E., SZCZEPANIK A. M., BURGHER K. L., PETKO W., HERONX J. A. and CAVALIERI F. (1996): Transcriptional inhibition of the beta-amyloid precursor protein by interferon gamma. Biochem. Biophys. Res. Commun., 224, 246-251.
28. ROZENMILLER J. M., VON DER VOLLE P. and EIKELENBOOM P. (1992): Activated microglia and cerebral amyloid deposits in Alzheimer's disease. Res. Immunol., 163, 646-649.
29. SCHMITT T. L., STEINER E., KLINGER P., SZTANKAY A. and GRUBECK-LOEBSTEIN B. (1996): The production of an amyloidc'genic metabolite of the Alzheimer amyloid precursor protein (APP) in tyroid cells is stimulated by interleukin 1 but inhibited by Interferon gamma. J. Clin. Endocrinol. Metab., 81, 1666-1669.
30. YAN S. D., YAN S. F., CHEN X., FU J., CHEN M., KUPPUSAMY P., SMITH M. A., PERRY G., GORMAN G. C., NAWROTH P., ZWEIER J. and STERN D. (1995): Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid peptide. Nat. Med., 1, 693-699.
31. WEGIEL J. and WIŚNIEWSKI H. M. (1998): Zmiany neurowłókienkowe w chorobie Alzheimera. In LESZEK J.: Choroba Alzheimera. Volumed, Wrocław, 97-103.
32. WISCHIK C. (1989): Cell biology of the Alzheirner tangle. Curr. Opin. Cell. Biol., 1, 115-122.
33. WIŚNIEWSKI H. M. and WȨGIEL J. (1998): β-Amyloidoza w chorobie Alzheimera. In LESZEK J.: Choroba Alzheimera. Volumed, Wrocław, 107-123.
34. WIŚNIEWSKI H. M. and WȨGIEL J. (1998): Neurologiczne krytena rozpoznawania choroby Alzheimera. In Leszek J.: Choroba Alzheimera. Volumed, Wrocław, 89-95.
35. WAN S. D. (1994): The presence of glycated tau in Alzheimer's disease: a mecnanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA, 91, 7787-7791.